Metraipolis › archive › dc_bf753ae6b69c

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39752322
DOI
10.1093/rheumatology/keaf006
License (as archived)
solo-consultazione
Archived
2026-11-08T02:33:46.984Z
SHA-256 of the archived text
3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1
Stable URL of this page
https://metraipolis.com/documento/dc_bf753ae6b69c

How to cite

Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322 — Europe PMC (en), https://europepmc.org/article/MED/39752322 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bf753ae6b69c (Metraipolis archive dc_bf753ae6b69c, sha256 3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1)
BibTeX
@misc{dcbf753ae6b69c,
  title = {Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis — Europe PMC PMID:39752322},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39752322},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bf753ae6b69c; sha256 3f5e6980d67cf27e680dd65b858b31272fcb0610b60687b0afc431ee56bc3cf1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39752322. Agents can read the archived copy with the MCP tool read_document.